Pfizer (NYSE:PFE) Trading Down 1.4% – Time to Sell?

Pfizer Inc. (NYSE:PFE) shares were down 1.4% on Friday . The stock traded as low as $28.38 and last traded at $28.42. 23,419,310 shares changed hands during trading, a decline of 44% from the average session volume of 41,591,715 shares. The stock had previously closed at $28.81.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer received FDA approval for the 2026–2027 COMIRNATY XFG COVID-19 vaccine formulation for high-risk age groups. The approval supports continued vaccine revenue and adds to the company’s recent positive news flow. Pfizer After FDA Vaccine Approval Faces A Fair Value Reality Check
• Positive Sentiment: Pfizer launched the VESPER-JM Phase 3 study of berobenatide in Japan, strengthening its effort to compete in the obesity-drug market. Successful development could provide a meaningful long-term growth opportunity beginning later this decade. Pfizer Steps Up in Obesity Race With New Phase 3 Berobenatide Trial in Japan
• Positive Sentiment: Pfizer’s broader pipeline remains focused on obesity and oncology, with berobenatide and next-generation cancer treatments viewed as potential growth drivers from 2028 onward. Pfizer’s Pipeline Strategy Centers on Obesity and Oncology
• Positive Sentiment: Pfizer licensed its early-stage CD228V antibody-drug conjugate to Medicus Pharma in a deal valued at up to $1 billion plus royalties. The agreement could generate milestone and royalty income while sharing development responsibilities. Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
• Neutral Sentiment: Pfizer completed a Phase 1 migraine-tablet study and is conducting a Phase 3 trial of tilrekimig for eczema. These updates demonstrate pipeline activity, but they do not yet provide confirmed commercial revenue. Pfizer’s Tilrekimig Eczema Trial
• Negative Sentiment: After gaining roughly 25% over the past year and trading near recent highs, valuation-based upside appears more limited. Investors are also weighing Pfizer’s elevated dividend yield and management’s commitment to maintaining the payout against ongoing post-pandemic earnings pressure.

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. Wolfe Research reissued an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. Guggenheim dropped their price target on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a research note on Tuesday, June 9th. Finally, Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.28.

Pfizer Stock Performance

The company has a market capitalization of $161.98 billion, a PE ratio of 37.40, a price-to-earnings-growth ratio of 1.91 and a beta of 0.34. The stock’s fifty day simple moving average is $25.98 and its 200-day simple moving average is $26.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s dividend payout ratio is currently 226.32%.

Institutional Investors Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Handelsbanken Fonder AB raised its position in Pfizer by 10.4% in the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after purchasing an additional 232,528 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after buying an additional 745,213 shares during the period. Leuthold Group LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $4,887,000. North Dakota State Investment Board purchased a new stake in shares of Pfizer during the 4th quarter valued at about $5,348,000. Finally, Park National Corp OH raised its holdings in shares of Pfizer by 332.1% during the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after buying an additional 186,053 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.